LDS/Medical Tests/Temazepam, Urine

Temazepam, Urine

Temazepam belongs to the class of drugs known as Benzodiazepines. Benzodiazepines are a class of medications that may produce the following effects: sedation, skeletal muscle relaxation, amnesia, antiemetic and anxiolytic. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS-depressants. Like all benzodiazepines, temazepam acts by increasing the sensitivity of the GABAA receptor in the CNS to GABA in the presence of temazepam; this interaction opens chloride channels which makes CNS neurons negatively charged and more resistant to excitation.

Temazepam is a short-acting benzodiazepine and is primarily used as a short-term treatment for insomnia. Temazepam is a white crystalline powder that is soluble in methylene chloride. Following an oral dose Temazepam is metabolized to oxazepam via the cytochrome P450 system in the liver. Only about 80% of an oral dose is eliminated in the urine. Temazepam and its major metabolite oxazepam are found in the urine as a glucuronide conjugate.

Temazepam is one of the benzodiazepine class that are typically used by illicit drug users, particularly heroin and cocaine abusers. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are only legally available through prescription. Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by immunoassays such as drugs of abuse screening tests in common usage. Benzodiazepines can elicit the following paradoxical effects: antegrade amnesia, hostility, irritability, suicidal ideation and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death.

  • Drug abuse evaluation
  • Patient Compliance
A qualitative positive result from an immunoassay screening test indicates only the presence of any of the benzodiazepines and does not necessarily correlate with the extent of physiological and psychological effects. Any positive screening test result should be confirmed by a quantitative and specific non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic levels: 50-1000 ng/mL (in serum)
Toxic levels: no data available

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific

Cut-Off Ranges
Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report.

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of quantitative detection is via LC/MS. This particular method of analysis is used to not only detect the parent drug compound, Temazepam, but also the major metabolite oxazepam. Temazepam, as well as all benzodiazepines can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis since some benzodiazepines are unstable in acid medium and rearrange to form benzophenones.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP2C19 may be tested for drug safety and efficacy before prescribing. Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
  • Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Principles of Forensic Toxicology, Fourth Edition. Barry Levine (Ed.). AACC Press, Washington DC, Chapter 14, Benzodiazepines, pp. 237-251 (2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC (ed.). Disposition of Tox Drugs and Chemicals in Man, Sixth Edition, Biomedical Publications, Foster City, CA (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.